Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth K Lee

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Gynecologic Oncology Reports|March 1, 2024
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancerPanagiotis A Konstantinopoulos, Niya Xiong, Carolyn Krasner, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 8, 2013
Endothelial TLR4 activation impairs intestinal microcirculatory perfusion in necrotizing enterocolitis via eNOS-NO-nitrite signalingIbrahim Yazji, Chhinder P Sodhi, Elizabeth K Lee, et al.
Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Gynecologic Oncology|August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trialElizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Nature Communications|March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trialRebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial CancerPanagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.
JCO Precision Oncology|April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial CancerPanagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.
Nature Communications|September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancerPanagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Nature Communications|December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trialPanagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
JAMA Oncology|July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial CancerPanagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Gynecologic Oncology Reports|March 1, 2024
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancerPanagiotis A Konstantinopoulos, Niya Xiong, Carolyn Krasner, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 8, 2013
Endothelial TLR4 activation impairs intestinal microcirculatory perfusion in necrotizing enterocolitis via eNOS-NO-nitrite signalingIbrahim Yazji, Chhinder P Sodhi, Elizabeth K Lee, et al.
Journal of the National Cancer Institute|May 6, 2024
Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)Elisa Fontana, Ezra Rosen, Elizabeth K Lee, et al.
Gynecologic Oncology|August 11, 2020
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trialElizabeth K Lee, Niya Xiong, Su-Chun Cheng, et al.
Nature Communications|March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trialRebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2022
A Phase II, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor-Positive Recurrent Endometrial CancerPanagiotis A Konstantinopoulos, Elizabeth K Lee, Niya Xiong, et al.
JCO Precision Oncology|April 10, 2025
Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial CancerPanagiotis A Konstantinopoulos, Mingyang Cai, Elizabeth K Lee, et al.
Nature Communications|September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancerPanagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
Nature Communications|December 3, 2025
Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trialPanagiotis A Konstantinopoulos, Ningxuan Zhou, Richard T Penson, et al.
JAMA Oncology|July 28, 2022
Evaluation of Treatment With Talazoparib and Avelumab in Patients With Recurrent Mismatch Repair Proficient Endometrial CancerPanagiotis A Konstantinopoulos, Allison A Gockley, Niya Xiong, et al.
Pageof 4